Panacea
Innovation can end China's healthcare downcycle - AVCJ Forum
Investors in Chinese healthcare are looking for innovators with global competencies to lead an industry recovery following a challenging past 12 months, the AVCJ Private Equity & Venture Forum China 2023 heard.
Fund focus: Panacea defies biotech downturn
Having raised its second fund amid weakening investor sentiment for biotech, Panacea Venture expects deployment to be guided by a widening valuation gap between the US and China
Panacea closes second healthcare fund on $276m
Panacea Venture, a healthcare-focused investment firm established by James Huang, formerly a partner at KPCB China, has closed its second fund with approximately USD 276m in commitments.
China biotech: Going global
A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
China's Panacea, Dell family office raise $200m SPAC
Panacea Venture, a China-focused early-stage healthcare investor, has teamed up with Michael Dell’s family office to raise $200 million for a special purpose acquisition company (SPAC).
VMS leads $190m round for China CDMO player Chime
VMS Group, a Hong Kong-based asset manager, has led a $190 million extended Series A round of funding for Chime Biologics, a Chinese contract development and manufacturing organization (CDMO).
Panacea leads $40m Series C for China's XWPharma
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Healthcare investors warn Asia unprepared for winter - AVCJ Forum
Private equity professionals focusing on healthcare told the AVCJ Southeast Asia Virtual Forum that COVID-19’s full impact has yet to be understood. The private and public sectors will need to work together to see out a difficult year.
Nan Fung, Pivotal China lead $80m round for Oncologie
Oncologie, a cancer drug developer with bases in Shanghai and Boston, has secured $80 million in Series B funding led by Nan Fung Life Sciences and Pivotal Bioventure Partners China.
Panacea closes debut China healthcare fund at $180m
Panacea Venture, a Chinese GP founded by KPCB alumnus James Huang that specializes in early-stage healthcare investments, has closed its debut fund at approximately $180 million.
US-China biotech: Troubled transfers
Chinese investment in US biotech – and its ability to import intellectual property for domestic drug development – looks set to be a casualty of worsening relations between the two nations
Profile: KPCB China's James Huang
James Huang, a managing partner at KPCB China, has launched his own healthcare-focused investment firm to put his incubation and operational skills to work with a new generation of Chinese start-ups